As the Covid-19 pandemic continues to force drastic change in everyday life, the effects on the pharmaceutical industry are no less profound. Although drug makers are still regularly demonized over their pricing, their proverbial stock has, nonetheless, risen in the public eye thanks to the desperate need for treatments and vaccines to combat the coronavirus. But what are those changes looking like? And what might they mean going forward? To gain some insight, we chatted with Kenneth Moch, a former board member of the BIO trade group who once ran several small drug companies. Moch is now a senior advisor to the Global Health Crisis Coordination Center, a coalition of companies and nonprofits that assists public officials during health crises. This is an edited version of our conversation. 

How is the pandemic changing industry thinking about where to devote resources?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that this is a deep post? “It’s a multi-linear equation for which we don’t have all the variables filled in.” Thanks to our scribe!

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy